ClinicalTrials.gg

Program

Vortioxetine

Also written as “Vortioxetine (Lu AA21004)”, “Lu AA21004” and “Vortioxetine 10 mg/day”.

Its studies are mostly in Depressive Disorder, Major · Generalized Anxiety Disorder · Depression · Anxiety Disorders · Attention Deficit Disorder with Hyperactivity, led by 4 companies.

Furthest: phase 4, since Jan 5, 201562 company-led studies, 1 open or runningNext primary completion: Sep 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck350 open or runningphase 4since Jan 5, 2015Jan 8, 2008none ahead
Takeda251 open or runningphase 4since Feb 20, 2015May 2, 2008Sep 30, 2029phase 3 · NCT07204314
Scotmann Pharmaceuticals10 open or runningphase 3since Oct 26, 2021Oct 26, 2021none ahead
Seasons Biotechnology (Taizhou)10 open or runningphase 1since Jun 6, 2022Jun 6, 2022none ahead

Also a collaborator on its studies: icon-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since May 2, 2008.

  1. Nov 21, 2016Phase 4 study in Depressive Disorder, MajorTakeda · NCT02972632 · 123 enrolled · United States
  2. Mar 10, 2017Phase 3 study in Depressive Disorder, MajorH. Lundbeck · NCT03108625 · 94 enrolled · Bulgaria, Estonia, France and more
  3. Feb 13, 2018Phase 1 study in Healthy Adult ParticipantsTakeda · NCT03437564 · 28 enrolled · Japan
  4. Dec 5, 2018Phase 2 study in Depressive Disorder, MajorH. Lundbeck · NCT03766867 · 80 enrolled · Bulgaria, Estonia, Latvia
  5. Feb 7, 2019Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT03835715 · 150 enrolled · France, Italy, Lithuania and more
  6. Mar 19, 2019Phase 1 study in HealthyH. Lundbeck · NCT03884491 · 16 enrolled · United Kingdom
  7. Jan 6, 2020Phase 4 study in Anxiety DisordersH. Lundbeck · NCT04220996 · 100 enrolled · Estonia, France, Italy and more
  8. Feb 26, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04288895 · 400 enrolled · India
  9. Mar 2, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04294654 · 82 enrolled · Estonia, France, Italy and more
  10. Jun 23, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04448431 · 605 enrolled · Argentina, Belgium, Bulgaria and more
  11. Aug 16, 2021Phase 3 study in DepressionH. Lundbeck · NCT05014919 · 35 enrolled · United States, Colombia, Latvia and more
  12. Oct 26, 2021Scotmann Pharmaceuticals's first study: phase 3 study in Depressive Disorder, MajorNew to Scotmann PharmaceuticalsScotmann Pharmaceuticals · NCT05104918 · 500 enrolled
  13. Jun 6, 2022Seasons Biotechnology (Taizhou)'s first study: phase 1 study in Depressive Disorder, MajorNew to Seasons Biotechnology (Taizhou)Seasons Biotechnology (Taizhou) · NCT05417087 · 48 enrolled · India
  14. Sep 30, 2025Phase 3 study in Depressive Disorder, MajorTakeda · NCT07204314 · 180 planned · Japan

Ahead

  1. Sep 30, 2029Primary completion: phase 3 study in Depressive Disorder, MajorTakeda · NCT07204314

TargetBeta

“A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity”NCIt, by rule
“Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist”ChEMBL 37, by rule

Studies

The newest 60 of 62 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07204314Depressive Disorder, Major · Japan3RecruitingTakedaSep 30, 2029180
NCT05417087Depressive Disorder, Major · India1CompletedSeasons Biotechnology (Taizhou)Sep 2, 202248
NCT05104918Depressive Disorder, Major3UNKNOWNScotmann PharmaceuticalsApr 2022500
NCT05014919Depression · United States, Colombia, Latvia and more3TerminatedH. LundbeckMar 31, 202235
NCT04448431Depressive Disorder, Major · Argentina, Belgium, Bulgaria and more4CompletedH. LundbeckJan 6, 2022605
NCT04294654Depressive Disorder, Major · Estonia, France, Italy and more4CompletedH. LundbeckJul 6, 202282
NCT04288895Depressive Disorder, Major · India4CompletedH. LundbeckFeb 11, 2022400
NCT04220996Anxiety Disorders · Estonia, France, Italy and more4CompletedH. LundbeckMar 9, 2021100
NCT03884491Healthy · United Kingdom1CompletedH. LundbeckJun 25, 201916
NCT03835715Depressive Disorder, Major · France, Italy, Lithuania and more4CompletedH. LundbeckFeb 21, 2020150
NCT03766867Depressive Disorder, Major · Bulgaria, Estonia, Latvia2CompletedH. LundbeckJul 31, 201980
NCT03437564Healthy Adult Participants · Japan1CompletedTakedaApr 13, 201828
NCT03108625Depressive Disorder, Major · Bulgaria, Estonia, France and more3CompletedH. LundbeckApr 16, 202094
NCT02972632Depressive Disorder, Major · United States4CompletedTakedaFeb 6, 2018123
NCT02932904Healthy Volunteers · United States4CompletedTakedaMay 31, 2017361
NCT02919501Depressive Disorder, Major · Estonia, Finland2CompletedH. LundbeckApr 27, 201755
NCT02871297Depressive Disorder, Major · United States, Bulgaria, Canada and more3TerminatedH. LundbeckMar 25, 2022662
NCT02709746Depressive Disorder, Major · United States, Bulgaria, Canada and more3CompletedH. LundbeckJul 2, 2019784
NCT02709655Depressive Disorder, Major · United States, Bulgaria, Canada and more3CompletedH. LundbeckJan 21, 2022683
NCT02389816Depressive Disorder, Major · Japan3CompletedTakedaMar 16, 2018493
NCT02386488Pharmacokinetics · China1CompletedH. LundbeckMay 201564
NCT02371980Depressive Disorder, Major · United States4CompletedTakedaMar 1, 20191,106
NCT02332954Depressive Disorder, Major · Canada4CompletedH. LundbeckJul 6, 2017226
NCT02327013Attention Deficit Disorder with Hyperactivity · United States2CompletedH. LundbeckSep 2016227
NCT02279966Depressive Disorder, Major · Estonia, Finland, Germany and more3CompletedH. LundbeckFeb 2016152
NCT02279953Depressive Disorder, Major · Estonia, Finland, Germany and more3CompletedH. LundbeckApr 2016151
NCT02272517Depressive Disorder, Major · Finland, Germany, Serbia and more3CompletedH. LundbeckMar 2016101
NCT02170220Severe Hepatic Impairment · United States1CompletedTakedaNov 201412
NCT02072278Healthy Men · France1CompletedH. LundbeckNov 201432
NCT01676571Healthy · China1CompletedH. LundbeckNov 201216
NCT01607125Depression · United Kingdom1CompletedH. LundbeckSep 201396
NCT01571453Depressive Disorder, Major3CompletedH. LundbeckOct 2013437
NCT01564862Depressive Disorder, Major · United States, Bulgaria, Finland and more2CompletedTakedaFeb 2014602
NCT01488071Depressive Disorder, Major3CompletedH. LundbeckDec 2012495
NCT01491035Depressive Disorder · United States, Germany2CompletedH. LundbeckDec 201448
NCT01422213Depressive Disorder, Major3CompletedH. LundbeckMay 2013598
NCT01395147Depressive Disorder, Major · Japan3CompletedTakedaMay 2013119
NCT01364649Sexual Dysfunction, Physiological · United States, Canada3CompletedTakedaDec 2013447
NCT01355081Depressive Disorder, Major · Japan3CompletedTakedaDec 2012366
NCT01323478Depressive Disorder, Major3CompletedH. LundbeckSep 201271
NCT01299805Healthy · United States1CompletedTakedaJun 201117
NCT01255787Depressive Disorder, Major · Croatia, Finland, Germany and more3CompletedTakedaMar 2012600
NCT01179516Depressive Disorder, Major · United States3CompletedTakedaMay 2012469
NCT01163266Depressive Disorder, Major · United States3CompletedTakedaJan 2012462
NCT01153009Depressive Disorder, Major · United States3CompletedTakedaMar 2012614
NCT01152996Depressive Disorder, Major3CompletedTakedaMay 20131,075
NCT01140906Depressive Disorder, Major3CompletedH. LundbeckSep 2011607
NCT00839423Depressive Disorder, Major2CompletedH. LundbeckAug 2007426
NCT00811252Depressive Disorder, Major3CompletedH. LundbeckFeb 2010453
NCT00788034Generalized Anxiety Disorder · Argentina, Chile, Colombia and more3CompletedH. LundbeckJun 2010459
NCT00761306Depressive Disorder, Major2CompletedH. LundbeckSep 200874
NCT00744627Generalized Anxiety Disorder · Estonia, Germany, Latvia and more3CompletedTakedaJul 2009301
NCT00735709Depressive Disorder, Major · Australia, Czech Republic, France and more3CompletedTakedaJul 2009560
NCT00734071Generalized Anxiety Disorder · United States3CompletedTakedaJan 2009304
NCT00731120Generalized Anxiety Disorder · United States3CompletedTakedaJan 2009457
NCT00730691Generalized Anxiety Disorder · United States3CompletedTakedaFeb 2009781
NCT00707980Depressive Disorder, Major · United States, Australia, Croatia and more3CompletedTakedaJul 2010836
NCT00694304Depressive Disorder, Major3CompletedH. LundbeckMar 2010535
NCT00672958Depressive Disorder, Major · United States, Canada, Mexico3CompletedTakedaNov 2008600
NCT00672620Depressive Disorder, Major · United States3CompletedTakedaNov 2008611

How it is read

Names in the registry

  • “Vortioxetine”, 35 entries
  • “Vortioxetine (Lu AA21004)”, 15 entries
  • “Lu AA21004”, 3 entries
  • “Vortioxetine 10 mg/day”, 2 entries
  • “Vortioxetine 20 mg/day”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.